WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today that SUNHARBO® (asundexian), 50 mg tablets, is now available to order in the United States. Hospitals, health systems and pharmacies have immediate access to order the product for inventory. SUNHARBO is the first approved Factor XIa inhibitor in the U.S. and represents the first in a new class of medicine.1 SUNHARBO is indicated in combination with antiplatelet therapy to reduce the risk of stroke in adults with recent non-cardioembolic isc

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.